Enobia Pharma Receives FDA Orphan Drug Designation For Hypophosphatasia Product Candidate ENB-0040

Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for ENB-0040, its enzyme replacement therapy (ERT) for hypophosphatasia, a rare, life-threatening genetic bone disease. In August 2008, Enobia dosed the first patient in a Phase I clinical trial of ENB-0040.

More: continued here

Filed under: Bones on October 1st, 2008